Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

clinical trial

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT04577404

P6099clinical trial phasephase III clinical trialQ42824827
P17countryCanadaQ16
JapanQ17
United States of AmericaQ30
ItalyQ38
GermanyQ183
FranceQ142
P582end time2023-09-01
P1050medical conditionsclerosisQ140067
amyotrophic lateral sclerosisQ206901
P2899minimum age18
P1132number of participants140
P4844research interventionantioxidantQ133948
edaravoneQ335099
mechanism of actionQ3271540
free radical scavengersQ25401178
neuroprotective agentQ50377190
P8005research subject recruitment statusactive, not recruitingQ76649790
P580start time2020-10-29
P8363study typeinterventional studyQ78089383
P1476titleA Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)